| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-11-12 | Cellectis (France) | €13 million | private placement | Private placement | ||
| 2014-11-10 | Histide (Switzerland) | CHF 4.5 Million (€3.7 million) | series A financing round | PARTER Capital Group (Switzerland) and a group of private investors | Series A financing round | |
| 2014-11-07 | CTI BioPharma - previously known as Cell Therapeutics (USA - WA) | $35 million | private placement | Cancer - Oncology | Private placement | |
| 2014-11-05 | MDXHealth (Belgium) | € 12.33 million ($ 15.43 million) | capital increase | Cancer - Oncology - Diagnostic - Technology - Services | Capital increase | |
| 2014-11-05 | Active Biotech (Sweden) | capital increase | Cancer - Oncology - Neurodegenerative diseases | Capital increase | ||
| 2014-11-04 | Mérieux Développement | € 150 million | Institut Mérieux (France) Sienne Capital (Luxemburg) | Private placement | ||
| 2014-10-30 | Cortendo (Sweden) | $11 million (NOK 73.4 million - € 8.62 million) | private placement | HealthCap (Sweden), Third Swedish National Pension Fund (AP3) (Sweden), Storebrand (Norway), Arctic Fund Management (Norway) | Rare diseases | Private placement |
| 2014-10-29 | Bavarian Nordic (Denmark) | DKK 250,999,997.35 (€ 33.7 million) | capital increase | Johnson & Johnson Development Corporation (USA - NJ) | Infectious diseases | Capital increase |
| 2014-10-28 | DCPrime (The Netherlands) | undisclosed | financing round | SkylineDx (The Netherlands), Van Herk Investments (The Netherlands) | Cancer - Oncology | Financing round |
| 2014-10-28 | Imevax (Germany) | €7.5 million | series A financing round | Wellington Partners (UK), BioMedPartners (Switzerland), EMBL Ventures (Germany), Santo Venture Capital (Germany) | Infectious diseases | Series A financing round |
| 2014-10-28 | Advent Life Sciences (UK) | £145.5 million (€184.7 million) | fundraising | Fundraising | ||
| 2014-10-27 | Probiodrug (Germany) | € 22.5 million | IPO | Neurodegenerative diseases | IPO | |
| 2014-10-27 | OPTIVAC projet led by Imaxio (France), the VirPath laboratory at the Université Claude Bernard of Lyon (France) and the International Center for Infectiology Research (CIRI) (France) | €600,000 | grant | National Research Agency (France) | Infectious diseases | Grant |
| 2014-10-24 | Oryzon Genomics (Spain) | € 1.1 million | grant | Ministry of Economy and Competitiveness of the Spanish Government (Spain) | Grant | |
| 2014-10-23 | Erytech Pharma (France) | € 30 million | capital increase | Cancer - Oncology | Capital increase | |
| 2014-10-23 | DBV Technologies (France) | € 90 million | IPO | Allergic diseases - Immunological diseases | IPO | |
| 2014-10-22 | Hybrigenics (France) | €4.62 million | private placement | Crede Capital Group (USA) | Technology - Services - Cancer - Oncology | Private placement |
| 2014-10-22 | Tetraphase Pharmaceuticals (USA - MA) | $86.3 million | private placement | Infectious diseases | Private placement | |
| 2014-10-20 | Immupharma (UK) | €400,000 | grant | region of Aquitaine (France) | Grant | |
| 2014-10-16 | Epigenomics (Germany - USA - MD | $ 5.3 million (€ 4.2 million) | capital increase | BioChain Institute (USA - CA) | Cancer - Oncology - Diagnostic | Capital increase |
